Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma
- 1 November 2018
- journal article
- research article
- Published by Elsevier BV in American Journal of Ophthalmology
- Vol. 195, 154-160
- https://doi.org/10.1016/j.ajo.2018.07.045
Abstract
No abstract availableKeywords
Funding Information
- Alcon Research Institute (P30EY014801, R01 CA125970)
- Research to Prevent Blindness (P30EY014801, R01 CA125970)
- National Institutes of Health (P30EY014801, R01 CA125970)
This publication has 27 references indexed in Scilit:
- The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratification and Individualized Patient Care in Uveal MelanomaPLoS Currents, 2013
- Collaborative Ocular Oncology Group Report Number 1: Prospective Validation of a Multi-Gene Prognostic Assay in Uveal MelanomaOphthalmology, 2012
- Frequent Mutation of BAP1 in Metastasizing Uveal MelanomasScience, 2010
- An Accurate, Clinically Feasible Multi-Gene Expression Assay for Predicting Metastasis in Uveal MelanomaThe Journal of Molecular Diagnostics, 2010
- Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastasesEye, 2007
- Transcriptomic versus Chromosomal Prognostic Markers and Clinical Outcome in Uveal MelanomaClinical Cancer Research, 2007
- Biomarkers in Cancer Staging, Prognosis and Treatment SelectionNature Reviews Cancer, 2005
- Outcome prediction and the future of the TNM staging system.JNCI Journal of the National Cancer Institute, 2004
- Survival rates with uveal melanoma in the United States: 1973–1997Ophthalmology, 2003
- Tumor doubling times in metastatic malignant melanoma of the uvea Tumor progression before and after treatmentOphthalmology, 2000